Bulletin 381. CKD AKI sick day guidance

This bulletin discusses the optimal use of medicines to manage CKD and AKI and issuing ‘sick-day guidance’ to people with CKD during periods of acute illness. With the focus on using generic dapagliflozin as a best value sodium glucose co-transporter-2 (SGLT-2) inhibitor in CKD treatment, it also provides potential savings from using generic dapagliflozin by country.